Get the Stockscreener App
3.1265
1.84%
0.0565
Lipocine Inc stock is traded at $3.1265, with a volume of 3,971.
It is up +1.84% in the last 24 hours and down -28.29% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$3.07
Open:
$3.09
24h Volume:
3,971
Relative Volume:
0.13
Market Cap:
$16.15M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-1.0251
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
-0.11%
1M Performance:
-28.29%
6M Performance:
-14.34%
1Y Performance:
-18.37%
1-Day Range:
$2.9836
$3.10
1-Week Range:
$2.96
$3.25
52-Week Range:
$2.96
$11.79
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.01 | 16.15M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.88 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.62 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
633.30 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.22 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.70 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Marketscreener.com
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine Updates Corporate Presentation in Recent 8-K Filing - Defense World
Lipocine (NASDAQ:LPCN) Receives Updated Regulatory Guidance for LPCN 1154 - Defense World
Lipocine plans phase 3 study for postpartum depression drug - MSN
Lipocine Inc. Receives Updated Regulatory Guidance on LPCN 1154 -February 06, 2025 at 09:30 am EST - Marketscreener.com
Lipocine plans phase 3 study for postpartum depression drug By Investing.com - Investing.com South Africa
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - The Herald Journal
Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - Defense World
Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World
(LPCN) On The My Stocks Page - Stock Traders Daily
StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World
FDA Grants Fast Track Designation to Lipocine (NASDAQ:LPCN) for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - Defense World
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
FDA fast tracks Lipocine's sarcopenia treatment - Investing.com
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire
FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - The Eastern Progress Online
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - The Eastern Progress Online
Where are the Opportunities in (LPCN) - Stock Traders Daily
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - GuruFocus.com
Lipocine Announces Supply and Distribution Agreement with Pharma - GuruFocus.com
Lipocine (NASDAQ:LPCN) Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
When the Price of (LPCN) Talks, People Listen - Stock Traders Daily
Lipocine: Q3 Earnings Snapshot - CT Insider
Lipocine Inc. (LPCN) Quarterly 10-Q Report - Quartz
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipocine (NASDAQ:LPCN) Presents Positive Data on LPCN 2401 at Obesity Society Conference - Defense World
Lipocine inks deal to bring TLANDO to South Korea - Investing.com
Lipocine Partners With SPC Korea For TLANDO In South Korea - Contract Pharma
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Morningstar
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study i - GuruFocus.com
Trading (LPCN) With Integrated Risk Controls - Stock Traders Daily
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):